OncoMed Pharmaceuticals Company Profile (NASDAQ:OMED)

About OncoMed Pharmaceuticals (NASDAQ:OMED)

OncoMed Pharmaceuticals logoOncoMed Pharmaceuticals, Inc. (OncoMed) is a clinical-stage biopharmaceutical company. The Company focuses on discovering and developing therapeutics that address the fundamental biology driving cancer's growth, resistance, recurrence and metastasis. The Company's therapeutic candidates and preclinical programs include Demcizumab (Anti-DLL4, OMP-21M18), Tarextumab (Anti-Notch2/3, OMP-59R5), Vantictumab (anti-Fzd7, OMP-18R5), Ipafricept (Fzd8-Fc, OMP-54F28), Brontictuzumab (Anti-Notch1, OMP-52M51), Navicixizumab (Anti-DLL4/VEGF Bispecific, OMP-305B83), Anti-RSPO3 (OMP-131R10), Anti-TIGIT (OMP-313M32) and GITRL-Fc trimer (OMP-336B11). Demcizumab is a humanized monoclonal antibody that inhibits Delta-like Ligand 4 (DLL4) in the Notch signaling pathway. Tarextumab is a human monoclonal antibody that binds to both the Notch2 and Notch3 receptors.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research - NEC
  • Sub-Industry: N/A
  • Symbol: NASDAQ:OMED
  • CUSIP: N/A
  • Web: www.oncomed.com
Capitalization:
  • Market Cap: $137.7 million
  • Outstanding Shares: 37,623,000
Average Prices:
  • 50 Day Moving Avg: $3.54
  • 200 Day Moving Avg: $6.09
  • 52 Week Range: $3.14 - $12.71
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.41
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $25.02 million
  • Price / Sales: 5.44
  • Book Value: ($1.08) per share
  • Price / Book: -3.35
Profitability:
  • EBIDTA: ($97,140,000.00)
  • Net Margins: -393.74%
  • Return on Assets: -52.89%
Debt:
  • Current Ratio: 3.27%
  • Quick Ratio: 3.27%
Misc:
  • Average Volume: 389,924 shs.
  • Beta: 2.9
  • Short Ratio: 3.94
 
Frequently Asked Questions for OncoMed Pharmaceuticals (NASDAQ:OMED)

What is OncoMed Pharmaceuticals' stock symbol?

OncoMed Pharmaceuticals trades on the NASDAQ under the ticker symbol "OMED."

How were OncoMed Pharmaceuticals' earnings last quarter?

OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) issued its earnings results on Monday, May, 8th. The company reported ($0.61) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.62) by $0.01. The firm earned $6.20 million during the quarter, compared to the consensus estimate of $5.85 million. The firm's revenue for the quarter was down 2.4% on a year-over-year basis. During the same period in the previous year, the company posted ($0.90) EPS. View OncoMed Pharmaceuticals' Earnings History.

Where is OncoMed Pharmaceuticals' stock going? Where will OncoMed Pharmaceuticals' stock price be in 2017?

8 brokers have issued 12 month price targets for OncoMed Pharmaceuticals' shares. Their predictions range from $5.00 to $16.00. On average, they anticipate OncoMed Pharmaceuticals' share price to reach $7.71 in the next year. View Analyst Ratings for OncoMed Pharmaceuticals.

What are analysts saying about OncoMed Pharmaceuticals stock?

Here are some recent quotes from research analysts about OncoMed Pharmaceuticals stock:

  • 1. Cantor Fitzgerald analysts commented, "Restructuring plan should lengthen cash runway by at least a year, and we view a focus on assets with potential milestone opportunities as a positive given." (4/25/2017)
  • 2. According to Zacks Investment Research, "OncoMed Pharmaceuticals, Inc. is a biopharmaceutical company which focuses on the discovering and developing monoclonal antibody therapeutics for cancer stem cells. It utilizes its technologies to identify, isolate and evaluate CSCs, validate multiple potential targets and pathways critical to CSC self-renewal and differentiation and develop antibody and other protein-based therapeutics. The company serves the healthcare industry and cancer therapy patients. OncoMed Pharmaceuticals, Inc. is based in Redwood City, United States. " (4/13/2017)
  • 3. HC Wainwright analysts commented, "We believe a positive readout from the Phase 2 YOSEMITE trial in pancreatic cancer could lead partner Celgene to opt-in to the demcizumab program in early 2017, followed by readout from the Phase 2 DENALI trial in NSCLC a year later," analyst Shaunak Deepak wrote in a note.Related Link: Shkreli Warned You: Mast Therapeutics Plummets 80% After Sickle Cell Drug Phase 3 Trial FailMeanwhile, the upcoming data of vantictumab in breast cancer patients could drive Bayer's opt-in to the Wnt program in 2017."We regard the pancreatic cancer indication as a source of potential upside for our vantictumab estimates. We see the second Wnt pathway antagonist ipafricept as a source of potential upside," Deepak highlighted.Further, the analyst expects GlaxoSmithKline may opt-in to develop tarextumab, as it may show activity in lung cancer despite the compound failed in pancreatic cancer trial."In addition to near-term opt-in milestones that could reach $172 million, we believe these partnerships could payoff with long-term benefits and free-up OncoMed's resources to pursue new development activities," (9/22/2016)

Are investors shorting OncoMed Pharmaceuticals?

OncoMed Pharmaceuticals saw a decline in short interest in the month of June. As of June 30th, there was short interest totalling 1,510,923 shares, a decline of 40.4% from the June 15th total of 2,535,442 shares. Based on an average daily trading volume, of 492,187 shares, the days-to-cover ratio is presently 3.1 days. Approximately 6.8% of the shares of the company are short sold.

Who are some of OncoMed Pharmaceuticals' key competitors?

Who are OncoMed Pharmaceuticals' key executives?

OncoMed Pharmaceuticals' management team includes the folowing people:

  • Paul J. Hastings, Chairman of the Board, President, Chief Executive Officer
  • Sunil Patel, Chief Financial Officer, Senior Vice President - Corporate Development and Finance
  • John A. Lewicki Ph.D., Executive Vice President, Chief Scientific Officer
  • Austin Gurney Ph.D., Senior Vice President, Molecular and Cellular Biology
  • Tim Hoey Ph.D., Senior Vice President, Cancer Biology
  • Alicia J Hager J.D. Ph.D., Vice President, General Counsel
  • Jack W. Lasersohn J.D., Lead Independent Director
  • Perry A. Karsen, Director
  • Rick E. Winningham, Director
  • Elisha P. Gould III, Independent Director

How do I buy OncoMed Pharmaceuticals stock?

Shares of OncoMed Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is OncoMed Pharmaceuticals' stock price today?

One share of OncoMed Pharmaceuticals stock can currently be purchased for approximately $3.62.


MarketBeat Community Rating for OncoMed Pharmaceuticals (NASDAQ OMED)
Community Ranking:  2.8 out of 5 ( )
Outperform Votes:  151 (Vote Outperform)
Underperform Votes:  118 (Vote Underperform)
Total Votes:  269
MarketBeat's community ratings are surveys of what our community members think about OncoMed Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for OncoMed Pharmaceuticals (NASDAQ:OMED) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 6 Hold Ratings, 2 Buy Ratings
Consensus Rating:Hold (Score: 2.25)
Consensus Price Target: $7.71 (113.10% upside)

Analysts' Ratings History for OncoMed Pharmaceuticals (NASDAQ:OMED)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/10/2017Piper Jaffray CompaniesSet Price TargetHold$5.00MediumView Rating Details
7/9/2017Jefferies Group LLCReiterated RatingBuy$5.00HighView Rating Details
5/15/2017HC WainwrightLower Price TargetBuy -> Buy$9.00 -> $6.00LowView Rating Details
5/9/2017Cantor FitzgeraldSet Price TargetHold$6.00HighView Rating Details
4/17/2017JMP SecuritiesDowngradeOutperform -> Market PerformLowView Rating Details
4/17/2017SunTrust Banks, Inc.DowngradeBuy -> HoldHighView Rating Details
4/11/2017Leerink SwannBoost Price TargetMarket Perform$6.00 -> $10.00HighView Rating Details
4/11/2017BMO Capital MarketsDowngradeOutperform -> Market Perform$6.00HighView Rating Details
6/1/2016MizuhoLower Price TargetNeutral$45.00 -> $40.00N/AView Rating Details
12/3/2015Wells Fargo & CompanyInitiated CoverageOutperformN/AView Rating Details
(Data available from 7/26/2015 forward)

Earnings

Earnings History for OncoMed Pharmaceuticals (NASDAQ:OMED)
Earnings by Quarter for OncoMed Pharmaceuticals (NASDAQ:OMED)
Earnings History by Quarter for OncoMed Pharmaceuticals (NASDAQ OMED)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2017Q1 2017($0.62)($0.61)$5.85 million$6.20 millionViewListenView Earnings Details
3/8/2017Q4 2016($0.68)($0.60)$6.57 million$6.22 millionViewListenView Earnings Details
11/1/2016Q3($0.77)($0.77)$9.48 million$5.92 millionViewN/AView Earnings Details
8/9/2016Q216($0.81)($0.91)$8.09 million$6.67 millionViewN/AView Earnings Details
5/5/2016Q1($0.73)($0.90)$8.28 million$6.40 millionViewN/AView Earnings Details
3/10/2016Q4$0.41$1.50$44.55 million$6.80 millionViewListenView Earnings Details
11/5/2015Q315($0.80)($0.81)$5.84 million$4.70 millionViewListenView Earnings Details
8/10/2015Q215($0.49)($0.72)$13.78 million$4.70 millionViewListenView Earnings Details
5/7/2015Q115($0.35)($0.49)$15.35 million$9.70 millionViewN/AView Earnings Details
3/12/2015Q414($0.27)($0.50)$11.92 million$8.51 millionViewN/AView Earnings Details
11/4/2014($0.30)($0.18)$17.84 million$19.02 millionViewN/AView Earnings Details
8/7/2014Q214($0.03)($0.53)$21.28 million$6.00 millionViewN/AView Earnings Details
5/8/2014Q114($0.13)($0.47)$18.08 million$6.02 millionViewN/AView Earnings Details
3/18/2014Q4 13$0.15($0.15)$20.37 million$19.00 millionViewN/AView Earnings Details
11/12/2013Q3$0.12($0.15)ViewN/AView Earnings Details
9/3/2013Q2 2013($0.02)($0.83)$8.31 million$2.90 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for OncoMed Pharmaceuticals (NASDAQ:OMED)
2017 EPS Consensus Estimate: ($1.94)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173($0.76)($0.63)($0.68)
Q2 20173($0.65)($0.37)($0.47)
Q3 20173($0.56)($0.29)($0.41)
Q4 20173($0.49)($0.29)($0.38)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for OncoMed Pharmaceuticals (NASDAQ:OMED)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for OncoMed Pharmaceuticals (NASDAQ:OMED)
Insider Ownership Percentage: 32.80%
Institutional Ownership Percentage: 44.45%
Insider Trades by Quarter for OncoMed Pharmaceuticals (NASDAQ:OMED)
Institutional Ownership by Quarter for OncoMed Pharmaceuticals (NASDAQ:OMED)
Insider Trades by Quarter for OncoMed Pharmaceuticals (NASDAQ:OMED)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/5/2017Perry A KarsenDirectorBuy10,000$3.46$34,600.00View SEC Filing  
5/26/2017Jonathan D RootDirectorSell13,880$3.71$51,494.80View SEC Filing  
5/25/2017Jack W LasersohnDirectorBuy34,614$3.37$116,649.18View SEC Filing  
5/23/2017Jack W LasersohnDirectorBuy20,000$3.55$71,000.00View SEC Filing  
5/19/2017Jonathan D RootDirectorSell7,487$3.70$27,701.90View SEC Filing  
5/16/2017Jack W LasersohnDirectorBuy23,507$3.49$82,039.43View SEC Filing  
4/4/2017Alicia J. HagerSVPSell4,316$9.06$39,102.96View SEC Filing  
4/4/2017Paul J. HastingsCEOSell6,473$9.06$58,645.38View SEC Filing  
4/4/2017Sunil PatelInsiderSell5,754$9.06$52,131.24View SEC Filing  
1/6/2017Paul J. HastingsCEOSell42,738$8.34$356,434.92View SEC Filing  
1/3/2017John A. LewickiEVPSell9,175$7.63$70,005.25View SEC Filing  
1/3/2017Timothy HoeySVPSell12,763$7.64$97,509.32View SEC Filing  
1/11/2016Jakob DupontSVPSell2,500$20.01$50,025.00View SEC Filing  
1/7/2016Alicia J. HagerVPSell1,623$22.28$36,160.44View SEC Filing  
1/7/2016John A. LewickiEVPSell2,162$22.28$48,169.36View SEC Filing  
1/6/2016Paul J. HastingsCEOSell2,412$22.28$53,739.36View SEC Filing  
11/27/2015Alicia J. HagerVPSell1,800$23.14$41,652.00View SEC Filing  
10/27/2015Alicia J. HagerVPSell5,400$21.00$113,400.00View SEC Filing  
10/26/2015Austin GurneyInsiderSell14,000$20.00$280,000.00View SEC Filing  
10/26/2015Jakob DupontSVPSell5,000$20.00$100,000.00View SEC Filing  
9/30/2015Jack W. LasersohnDirectorBuy11,210$16.01$179,472.10View SEC Filing  
9/29/2015Jack W. LasersohnDirectorBuy3,140$14.15$44,431.00View SEC Filing  
9/28/2015Jack W. LasersohnDirectorBuy10,000$14.74$147,400.00View SEC Filing  
7/10/2015Jakob DupontSVPSell2,500$20.13$50,325.00View SEC Filing  
7/6/2015Jakob DupontSVPSell2,500$21.22$53,050.00View SEC Filing  
6/29/2015Alicia J HagerVPSell1,800$22.67$40,806.00View SEC Filing  
6/22/2015Timothy HoeySVPSell5,000$26.07$130,350.00View SEC Filing  
6/16/2015John A LewickiEVPSell17,000$25.07$426,190.00View SEC Filing  
6/15/2015John A LewickiEVPSell8,500$24.92$211,820.00View SEC Filing  
5/27/2015Alicia J HagerVPSell1,800$23.07$41,526.00View SEC Filing  
5/18/2015Austin GurneyInsiderSell4,000$22.48$89,920.00View SEC Filing  
4/27/2015Alicia J HagerVPSell1,800$25.65$46,170.00View SEC Filing  
4/27/2015Timothy HoeySVPSell6,887$25.65$176,651.55View SEC Filing  
4/17/2015Austin GurneyInsiderSell4,000$25.51$102,040.00View SEC Filing  
4/10/2015Jakob DupontSVPSell1,500$26.51$39,765.00View SEC Filing  
4/2/2015John A LewickiEVPSell17,000$25.28$429,760.00View SEC Filing  
3/20/2015Sunil PatelInsiderSell18,000$27.76$499,680.00View SEC Filing  
3/17/2015Austin GurneyInsiderSell4,000$27.37$109,480.00View SEC Filing  
2/5/2015Timothy HoeySVPSell7,500$22.83$171,225.00View SEC Filing  
2/2/2015John A LewickiEVPSell4,000$22.49$89,960.00View SEC Filing  
1/20/2015Austin GurneyInsiderSell4,000$22.87$91,480.00View SEC Filing  
1/12/2015Jakob DupontSVPSell1,500$25.89$38,835.00View SEC Filing  
1/5/2015Jakob DupontSVPSell7,500$23.00$172,500.00View SEC Filing  
1/2/2015John A LewickiEVPSell4,000$22.10$88,400.00View SEC Filing  
12/31/2014Denise Pollard-KnightDirectorSell3,799$21.66$82,286.34View SEC Filing  
12/30/2014Denise Pollard-KnightDirectorSell17,607$21.63$380,839.41View SEC Filing  
12/18/2014Jonathan D RootDirectorSell13,052$21.05$274,744.60View SEC Filing  
12/17/2014Austin GurneyInsiderSell4,000$20.00$80,000.00View SEC Filing  
12/10/2014Denise Pollard-KnightDirectorSell32,940$21.78$717,433.20View SEC Filing  
12/9/2014Denise Pollard-KnightDirectorSell23,273$21.78$506,885.94View SEC Filing  
12/8/2014Denise Pollard-KnightDirectorSell1,727$21.68$37,441.36View SEC Filing  
12/5/2014Denise Pollard-KnightDirectorSell25,000$21.60$540,000.00View SEC Filing  
12/1/2014John A LewickiEVPSell4,000$21.19$84,760.00View SEC Filing  
11/5/2014Timothy HoeySVPSell2,500$19.51$48,775.00View SEC Filing  
10/29/2014Paul J HastingsCEOSell16,769$21.99$368,750.31View SEC Filing  
10/2/2014Austin GurneyInsiderSell4,000$20.00$80,000.00View SEC Filing  
10/2/2014John A LewickiEVPSell5,809$20.00$116,180.00View SEC Filing  
9/4/2014Jack W LasersohnDirectorBuy3,170$18.35$58,169.50View SEC Filing  
9/3/2014Jack W LasersohnDirectorBuy3,000$18.40$55,200.00View SEC Filing  
9/2/2014John A LewickiEVPSell2,191$20.01$43,841.91View SEC Filing  
8/22/2014Austin GurneyInsiderSell4,000$20.00$80,000.00View SEC Filing  
8/21/2014Deepika PakianathanDirectorBuy80,203$18.98$1,522,252.94View SEC Filing  
8/15/2014Jack W LasersohnDirectorBuy1,045$17.00$17,765.00View SEC Filing  
8/5/2014Timothy HoeySVPSell2,500$21.66$54,150.00View SEC Filing  
8/1/2014John A LewickiEVPSell4,000$20.98$83,920.00View SEC Filing  
7/29/2014Paul J HastingsCEOSell16,770$22.11$370,784.70View SEC Filing  
7/23/2014Jakob DupontSVPSell1,500$23.00$34,500.00View SEC Filing  
7/17/2014Austin GurneyInsiderSell4,000$20.46$81,840.00View SEC Filing  
7/1/2014John A LewickiEVPSell4,000$23.86$95,440.00View SEC Filing  
6/30/2014Denise Pollard-KnightDirectorSell11,485$23.59$270,931.15View SEC Filing  
6/26/2014Jakob DupontSVPSell1,500$23.00$34,500.00View SEC Filing  
6/25/2014Denise Pollard-KnightDirectorSell3,252$23.56$76,617.12View SEC Filing  
6/24/2014Denise Pollard-KnightDirectorSell64,561$24.08$1,554,628.88View SEC Filing  
6/17/2014Austin GurneyInsiderSell4,000$24.99$99,960.00View SEC Filing  
6/16/2014John A LewickiEVPSell4,000$24.59$98,360.00View SEC Filing  
6/10/2014Presidio Management Group ViiiMajor ShareholderSell13,052$24.57$320,687.64View SEC Filing  
5/12/2014Presidio Management Group Viiimajor shareholderSell46,327$21.99$1,018,730.73View SEC Filing  
7/23/2013Denise Pollard-KnightDirectorBuy58,824$17.00$1,000,008.00View SEC Filing  
7/23/2013Presidio Management Group ViiiMajor ShareholderBuy158,823$17.00$2,699,991.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for OncoMed Pharmaceuticals (NASDAQ:OMED)
Latest Headlines for OncoMed Pharmaceuticals (NASDAQ:OMED)
Source:
DateHeadline
americanbankingnews.com logoFinancial Contrast: Oncomed Pharmaceuticals (NASDAQ:OMED) vs. CytRx Corporation (CYTR)
www.americanbankingnews.com - July 18 at 4:57 PM
americanbankingnews.com logoOncomed Pharmaceuticals Inc (OMED) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - July 18 at 10:04 AM
americanbankingnews.com logoOncoMed Pharmaceuticals, Inc. (OMED) Short Interest Down 40.4% in June
www.americanbankingnews.com - July 17 at 7:24 AM
finance.yahoo.com logoETFs with exposure to OncoMed Pharmaceuticals, Inc. : July 12, 2017
finance.yahoo.com - July 13 at 7:38 AM
reuters.com logoBRIEF-Oncomed says GSK terminates license agreement with company
www.reuters.com - July 11 at 6:21 AM
americanbankingnews.com logoOncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) Rating Reiterated by Jefferies Group LLC
www.americanbankingnews.com - July 9 at 7:18 AM
americanbankingnews.com logoOncoMed Pharmaceuticals, Inc. (OMED) Expected to Post Quarterly Sales of $6.23 Million
www.americanbankingnews.com - July 5 at 11:46 AM
americanbankingnews.com logo Analysts Expect OncoMed Pharmaceuticals, Inc. (OMED) to Post -$0.47 EPS
www.americanbankingnews.com - July 3 at 8:26 PM
americanbankingnews.com logoOncoMed Pharmaceuticals, Inc. (OMED) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - June 23 at 11:27 AM
finance.yahoo.com logoETFs with exposure to OncoMed Pharmaceuticals, Inc. : June 16, 2017
finance.yahoo.com - June 16 at 7:58 PM
americanbankingnews.com logo$6.23 Million in Sales Expected for Oncomed Pharmaceuticals Inc (OMED) This Quarter
www.americanbankingnews.com - June 9 at 12:58 PM
americanbankingnews.com logo-$0.47 EPS Expected for Oncomed Pharmaceuticals Inc (OMED) This Quarter
www.americanbankingnews.com - June 7 at 8:46 PM
americanbankingnews.com logoOncomed Pharmaceuticals Inc (OMED) Director Perry A. Karsen Acquires 10,000 Shares
www.americanbankingnews.com - June 7 at 8:21 PM
finance.yahoo.com logoETFs with exposure to OncoMed Pharmaceuticals, Inc. : June 5, 2017
finance.yahoo.com - June 5 at 7:40 PM
americanbankingnews.com logoValuEngine Lowers Oncomed Pharmaceuticals Inc (OMED) to Strong Sell
www.americanbankingnews.com - June 3 at 7:38 PM
finance.yahoo.com logoOncoMed Pharmaceuticals, Inc. :OMED-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017
finance.yahoo.com - June 2 at 9:10 PM
globenewswire.com logoGlobal Double Barreled Antibodies Drug Sales (BLINCYTO & Removab) & Pipeline Analysis 2017-2022
globenewswire.com - June 1 at 8:48 AM
americanbankingnews.com logoOncomed Pharmaceuticals Inc (OMED) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - May 29 at 9:20 AM
americanbankingnews.com logoOncomed Pharmaceuticals Inc (OMED) Director Jack W. Lasersohn Acquires 34,614 Shares
www.americanbankingnews.com - May 26 at 8:02 PM
americanbankingnews.com logoOncomed Pharmaceuticals Inc (OMED) Director Jonathan D. Root Sells 13,880 Shares
www.americanbankingnews.com - May 26 at 1:51 PM
seekingalpha.com logoIs OncoMed A Contrarian Buy?
seekingalpha.com - May 26 at 5:31 AM
americanbankingnews.com logoOncomed Pharmaceuticals Inc (OMED) Director Acquires $71,000.00 in Stock
www.americanbankingnews.com - May 25 at 8:29 PM
americanbankingnews.com logoJonathan D. Root Sells 7,487 Shares of Oncomed Pharmaceuticals Inc (OMED) Stock
www.americanbankingnews.com - May 22 at 10:28 PM
americanbankingnews.com logoOncomed Pharmaceuticals Inc (OMED) Director Acquires $82,039.43 in Stock
www.americanbankingnews.com - May 18 at 8:11 PM
businesswire.com logoNewman Ferrara LLP Announces Corporate Governance Investigation of OncoMed Pharmaceuticals Inc. - Business Wire (press release)
www.businesswire.com - May 16 at 10:04 AM
finance.yahoo.com logoNewman Ferrara LLP Announces Corporate Governance Investigation of OncoMed Pharmaceuticals Inc.
finance.yahoo.com - May 16 at 10:04 AM
americanbankingnews.com logoOncomed Pharmaceuticals Inc (OMED) Price Target Lowered to $6.00 at HC Wainwright
www.americanbankingnews.com - May 15 at 10:12 AM
finance.yahoo.com logoEdited Transcript of OMED earnings conference call or presentation 8-May-17 12:30pm GMT
finance.yahoo.com - May 13 at 12:48 AM
americanbankingnews.com logoFY2017 Earnings Forecast for Oncomed Pharmaceuticals Inc (OMED) Issued By Cantor Fitzgerald
www.americanbankingnews.com - May 12 at 12:32 PM
americanbankingnews.com logoBrokers Offer Predictions for Oncomed Pharmaceuticals Inc's Q2 2017 Earnings (OMED)
www.americanbankingnews.com - May 12 at 8:51 AM
americanbankingnews.com logo Analysts Expect Oncomed Pharmaceuticals Inc (OMED) Will Announce Earnings of -$0.43 Per Share
www.americanbankingnews.com - May 11 at 8:20 PM
finance.yahoo.com logoHuman Antibody Discovery: Of Mice And Phage
finance.yahoo.com - May 11 at 9:06 AM
americanbankingnews.com logoJefferies Group Comments on Oncomed Pharmaceuticals Inc's Q2 2017 Earnings (OMED)
www.americanbankingnews.com - May 11 at 7:56 AM
americanbankingnews.com logoOncomed Pharmaceuticals Inc Forecasted to Earn Q2 2017 Earnings of ($0.37) Per Share (OMED)
www.americanbankingnews.com - May 11 at 7:56 AM
americanbankingnews.com logoOncomed Pharmaceuticals Inc (OMED) Given a $6.00 Price Target at Cantor Fitzgerald
www.americanbankingnews.com - May 9 at 11:02 PM
americanbankingnews.com logoOncomed Pharmaceuticals Inc (OMED) Posts Earnings Results, Beats Estimates By $0.01 EPS
www.americanbankingnews.com - May 8 at 9:24 PM
finance.yahoo.com logoOncoMed reports 1Q loss
finance.yahoo.com - May 8 at 12:11 PM
finance.yahoo.com logoInvestor Network: OncoMed Pharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - May 8 at 12:11 PM
finance.yahoo.com logoOncoMed Pharma stock drops 17% after clinical trial miss; Q1 revenue miss
finance.yahoo.com - May 8 at 12:11 PM
finance.yahoo.com logoOncoMed Doses First Patient with Anti-TIGIT Antibody in Phase 1 Clinical Trial - Yahoo Finance
finance.yahoo.com - May 5 at 12:13 AM
globenewswire.com logoOncoMed Pharmaceuticals to Report First Quarter Financial Results on May 8th, 2017 - GlobeNewswire (press release)
globenewswire.com - May 5 at 12:13 AM
reuters.com logoBRIEF-Oncomed doses first patient with anti-tigit antibody in phase 1 clinical trial
www.reuters.com - May 4 at 7:11 PM
finance.yahoo.com logoOncoMed Doses First Patient with Anti-TIGIT Antibody in Phase 1 Clinical Trial
finance.yahoo.com - May 4 at 7:11 PM
americanbankingnews.com logoOncomed Pharmaceuticals (OMED) Given Media Sentiment Rating of 0.25
www.americanbankingnews.com - May 4 at 1:10 AM
finance.yahoo.com logoOncoMed Pharmaceuticals to Report First Quarter Financial Results on May 8th, 2017
finance.yahoo.com - May 3 at 8:01 PM
americanbankingnews.com logoOncomed Pharmaceuticals Inc (OMED) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - May 2 at 10:04 AM
americanbankingnews.com logoOncomed Pharmaceuticals (OMED) Earning Very Positive News Coverage, Study Shows
www.americanbankingnews.com - April 30 at 10:22 AM
americanbankingnews.com logo-$0.62 Earnings Per Share Expected for Oncomed Pharmaceuticals Inc (OMED) This Quarter
www.americanbankingnews.com - April 28 at 1:03 AM
reuters.com logoBRIEF-BVF Partners reports 7.9 pct passive stake in Oncomed Pharmaceuticals as of April 17
www.reuters.com - April 27 at 7:31 PM
rttnews.com logoOncoMed Pharma To Reduce Its Workforce By About 50%
www.rttnews.com - April 25 at 11:42 AM

Social

Chart

OncoMed Pharmaceuticals (OMED) Chart for Wednesday, July, 26, 2017

This page was last updated on 7/26/2017 by MarketBeat.com Staff